Is it worth suppressing TSH in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment?
Objective Guidelines recommend TSH suppression before the first response to treatment assessment in papillary thyroid cancer (PTC) patients. The aim of this study was to assess the rate of structural disease (SD) in low- and intermediate-risk PTC patients according to TSH levels measured 1 year after primary treatment. Methods A consecutive, prospective series of low- and intermediate-risk PTC patients with 3-years follow-up was collected. TSH, thyroglobulin, anti-thyroglobulin antibodies, and neck ultrasonography 1 and 3 years after primary treatment were analyzed.